Product Description
Oncomatryx is developing OMTX-705 as a treatment for pancreatic, breast, and lung cancer. (Sourced from: https://oncomatryx.com/adc-omtx705/)
Mechanisms of Action: FAP Antagonist
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oncomatryx
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Spain, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Vision, Low
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OMTX705-001 | P1 |
Recruiting |
Vision, Low |
2024-10-01 |
43% |